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Donor Transplantation with Reduced-Intensity
Conditioning for Hematologic Malignancies
Jakob R. Passweg,1 Mei-Jie Zhang,2 Vanderson Rocha,3 Fangyu Kan,4
Richard E. Champlin,5 Luis M. Isola,6 Adrian P. Gee,7 John Gibson,8
Mary J. Laughlin,9 Hillard M. Lazarus,10 Alison Loren,11 David I. Marks,12
Alois Gratwohl,1 Mary Eapen2We examined the effect of donor characteristics on graft failure (\5% donor chimerism within 3 months
after transplantation), acute and chronic graft-versus-host disease (aGVHD, cGVHD), and survival after
unrelated donor reduced-intensity conditioning (RIC) transplantation in 709 patients with hematologic
malignancies. Donor–recipient pairs were HLA typed at HLA-A, -B, -C, and -DRB1 (allele-level). A total
of 501 patients were .95% donor chimerism, 145 patients were 5% to 95%, and 63 patients were\5%.
The only donor characteristic associated with transplantation outcome was donor–recipient HLA matching.
One- or 2-loci mismatched transplants led to higher grade 2-4 (relative risk [RR]5 1.27, P5.035) and grade
3-4 (RR5 1.85, P\.001) aGVHD and 2-loci mismatched transplants higher mortality (RR5 2.22, P\.001).
Graft failure was higher after transplantation of bone marrow (RR 5 2.33, P5 .002). Donor age, parity, and
donor sex match were not associated with transplantation outcome. Donor–recipient HLA matching is the
only donor characteristic predictive for survival after RIC regimens for hematologic malignancies.
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Hematopoietic stem cell transplantation (HSCT)
is a curative option for malignant and nonmalignant
diseases [1]. The last decade has seen an expansion of
HSCT, in part because of use of reduced-intensity
conditioning (RIC) regimens making that have made
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6/j.bbmt.2011.07.008tients with comorbidities who are unlikely to tolerate
myeloablative conditioning regimens [2-4]. RIC
regimens now account for approximately 40% of
allogeneic transplantations in adults with hema-
tologic malignancies. The characteristics of donors
that influence HSCT outcomes after myeloablative
conditioning regimens are described [5,6]. However,
little is known about the effect of unrelated adult donor
(URD) characteristics on the outcomes of RIC HSCT.
Therefore, using data reported to the Center for
International Blood and Marrow Transplant Research
(CIBMTR), we examined the association between
donor characteristics and outcomes after URD HSCT
with RIC regimens for hematologic malignancies.MATERIALS AND METHODS
Patients
Included are 709 patients with hematologic malig-
nancies (Table 1) who received an RIC regimen for
their first URD transplantation from 1999 to 2006 in
the United States, and facilitated by the National
Marrow Donor Program. The preparative regimen
was considered RIC when patients received busulfan
\9 mg/kg, melphalan \150 mg/m2, and total body
Table 1. Patient, Disease, and Transplant Characteristics
Variables Number (%)
Total 709
Patient age (years)
18-30 37 (5)
31-40 63 (9)
41-50 113 (16)
51-60 302 (43)
>60 194 (27)
Performance score
90-100 417 (59)
<90 223 (31)
Not reported 69 (10)
Disease
Acute myeloid leukemia 353 (50)
Acute lymphoid leukemia 37 (5)
Myelodysplastic syndrome 74 (10)
Chronic myeloid leukemia 70 (10)
Non-Hodgkin lymphoma 175 (25)
Disease status at transplantation
First complete remission, chronic phase,
refractory anemia
253 (36)
Second complete remission, chronic phase,
accelerated phase
222 (31)
Not in remission, refractory anemia with
excess blasts or in transformation
234 (33)
Graft source
Peripheral blood progenitor cells 550 (78)
Bone marrow 159 (22)
Conditioning regimen
Irradiation-containing* 209 (29)
Busulfan-containing† 188 (27)
Melphalan-containing‡ 217 (31)
Cyclophosphamide-containing§ 95 (13)
Graft-versus-host disease prophylaxis
Tacrolimuscontaining regimens¶ 419 (59)
Cyclosproinecontaining regimensk 290 (41)
Donor age (years)
18-30 233 (33)
31-40 277 (39)
41-50 165 (23)
51-60 34 (5)
Donor-recipient HLA match**
Matched at HLA-A, -B, -C, -DRB1 498 (70)
1-locus mismatch 170 (24)
2-loci mismatch 41 (6)
Donor-recipient sex match††
Male donor to male recipient 282 (40)
Male donor to female recipient 189 (27)
Female donor to male recipient 127 (18)
Female donor to female recipient 111 (16)
Donor-recipient cytomegalovirus serostatus
Negative donor to negative recipient 198 (28)
Negative donor to positive recipient 270 (38)
Positive donor to negative recipient 70 (10)
Positive donor to positive recipient 161 (23)
Unknown 10 (1)
Donor-recipient ABO match
Matched 286 (40)
Minor ABO incompatibility 182 (26)
Major ABO incompatibility 241 (34)
*Irradiation-containing.
Total body irradiation (TBI) (200 cGy, single fraction) + fludarabine 6
antithymocyte globulin (ATG)/monoclonocal antibody (n 5 166).
TBI (200 cGy, single fraction) + ATG (n 5 8).
TBI (200 cGy, single fraction) + busulfan (n 5 2).
TBI (300 cGy, 400 cGy or irradiation 450 cGy, single fraction) +
fludarabine 6 busulfan (n 5 18).
TBI (400 cGy, fractionated) + fludarabine + busulfan (n 5 13).
TBI (400 cGy, fractionated) + fludarabine (n 5 2).
†Busulfan-containing.
Busulfan + fludarabine + ATG/monoclonal antibody (n 5 93).
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cGy (single or fractionated dose) [7]. Patients received
either bone marrow (BM) or peripheral blood progen-
itor cells (PBPC). The decision to offer the RIC regi-
men and the choice of graft type was at the discretion
of the transplant center. Allele-level HLA typing at -A,
-B, -C, and -DRB1 were available for all donor–
recipient pairs; donor–recipient HLA typing was per-
formed at a central laboratory. Mismatches at interme-
diate (antigen) or high (allele) resolution were
considered equivalent and were described as allele-
mismatches [5]. Excluded were patients aged \18
years, those who had received a prior autologous or al-
logeneic transplantation, T cell-depleted BM and
CD34 selected PBPC and recipients of cord blood
grafts. The study was approved by the institutional
review boards of the Medical College of Wisconsin
and the National Marrow Donor Program.Endpoints
Primary endpoints were graft failure defined as the
absence of absolute neutrophil count$0.5  109/L or
donor chimerism \5% within 3 months posttrans-
plantation without clinical relapse for patients with ab-
solute neutrophil count $0.5  109/L and overall
survival. For patients with chimersim assay \95%
and .5% (mixed donor chimerism), subsequent assay
confirmed\5% (graft failure) or .95% (full donor
chimerism). Chimerism assays were performed on
BM or whole blood without taking cellular subsets
into account; the timing and method of assay was at
the discretion of the transplant center. The median
time to chimerism assay was 1.5 months (range:
0.9-3.0). In 79 patients (11%), the method employedusulfan + fludarabine (n 5 24).
usulfan + cylcophosphamide + ATG (n 5 4).
usulfan + cylcophosphamide (n 5 42).
usulfan + fludarabine + total lymphoid irradiation (n 5 25).
Melphalan-containing
elphalan + fludarabine (n 5 108).
elphalan + fludarabine + ATG/monoclonal antibody (n 5 98).
elphalan + other agents (n 5 11).
Cyclophosphamide-containing
yclophosphamide + fludarabine (n 5 39).
yclophosphamide + fludarabine + ATG/monoclonal antibody (n5 44).
yclophosphamide + other agents (n 5 12).
Tacrolimus-containing regimens
acrolimus alone (n 5 47).
acrolimus + mycophenolate mofetil (n 5 127).
acrolimus + methotrexate (n 5 245).
Cyclosporin-containing regimens
yclosporin alone (n 5 37).
yclosporin + mycophenolate mofetil (n 5 178).
yclosporin + methotrexate (n 5 75).
*Matching at DQ was not considered as a single mismatch at this locus
nd is not associated with adverse outcome [5].
†Among female donors, n5 97 are nulliparous, n5 132 have had 1 or
ore pregnancies, and parity was not reported for 9 patients.B
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ing patients, molecular methods. Secondary endpoints
were acute grade 2-4, grade 3-4 graft-versus-host
disease (GVHD), and chronic GVHD (cGVHD) [8,9].
Statistical Methods
Patient, disease, donor, and transplant character-
istics are shown in Table 1. The probability of overall
survival (OS) was calculated using the Kaplan-Meier
estimator [10]. Death from any cause was an event,
and surviving patients were censored at last follow-
up. A logistic regression model was constructed to
identify risk factors for graft failure at 3 months,
and the Cox model, for acute GVHD (aGVHD),
cGVHD, and overall mortality [11]. Models were
built using forward step-wise selection and variables
shown in Table 1, which attained a significance level
of #0.05 retained in the final model. All P values are
2 sided. The effect of transplant center on OS was
tested using the frailty method [12]. All analyses
were done using SAS version 9.1 (SAS Institute,
Cary, NC).RESULTS AND DISCUSSION
Our primary objective was to identify the effect of
donor characteristics on graft failure, aGVHD and
cGVHD, and survival to allow selection of the optimal
URD for RIC-HSCT in patients with hematologic
malignancies. The median follow-up of surviving
patients is 2.5 years. Donor-recipient matching
considered matching at HLA-A, -B, -C, and -DRB1
(allele-level typing). A total of 501 patients were
.95% donor chimerism, 145 patients 5%-95%
(mixed chimerism), and 63 patients\5% (graft fail-
ure). Graft failure rates were higher after transplanta-
tion of BM compared with PBPC (odds ratio [OR]:
2.33, 95% confidence interval [CI]: 1.35-4.01, P 5
.002). No other characteristic was associated with graft
failure. Transplantation of BMwas not associated with
higher mortality risks despite the higher risk of graft
failure. In the 145 patients with mixed donor chime-
rism, 101 had recurrent disease, which ultimately
resulted in graft failure; the median time to recurrent
disease was 57 days from transplantation. Eighteen
patients with mixed donor chimerism died from
transplant-related complications. Only 26 patients
are alive and disease-free at last follow-up. Forty-five
of 63 patients with graft failure (\5% donor chime-
rism) are dead (recurrent disease or organ failure)
and 18 are alive; 10 of these patients are in remission.
Despite higher graft failure rates associated with trans-
plantation of BM, graft type was not associated with
OS; 28 of 39 (72%) PBPC recipients and 17 of
24 (71%) are dead. Patients with graft failures received
alternative therapies and our data suggest salvage ratesdo not differ by graft type for first transplantation.
Consequently, in the current analysis, graft type was
not associated with OS.
Consistent with reports after myeloablative condi-
tioning regimens for hematologic malignancies [5],
risks of acute grade 2-4 and grade 3-4 aGVHD were
higher after transplantations mismatched at 1- or
2-loci (Table 2). Risks of acute 2-4 and grade 3-4
GVHD were lower with in vivo T cell depletion.
Grade 3-4 aGVHD was lower with tacrolimus-
containing GVHD prophylaxis regimens. Chronic
GVHD was not associated with HLA mismatch,
and this was consistent with reports after myeloabla-
tive transplant conditioning [5]. Chronic GVHD
was lower with in vivo T cell depletion regimens
(Table 2). We examined for an effect of in vivo
T cell depletion on survival and found none. Our find-
ings differ from a recent CIBMTR report [13]; use of
antithymocyte globulin (ATG) was associated with
significantly lower survival in recipients of non-TBI
conditioning regimens.That report had almost 800 pa-
tients who received in vivo T cell depletion compared
with the 419 patients in the current analysis, and differ-
ences in sample size likely account for the observed
difference between the 2 reports.
The only donor characteristic affecting OS was
donor–recipient HLA mismatch (Table 2 and
Figure 1). Compared with matched transplants,
mortality risks were higher after transplantations
mismatched at 2-loci but not for transplantations
mismatched at 1-locus. Only 170 donor–recipient pairs
were mismatched at 1-locus, and the relatively small
sample size may explain our inability to detect a signif-
icant difference. Mortality risks were also higher after
2-loci mismatched transplantations compared to
1-locus mismatched transplantations (relative risk
[RR]5 1.88, 95%CI: 1.27-2.78,P5 .002).We consid-
ered donor–recipient matching at HLA-A, -B, -C, and
-DRB1. Although we did not consider matching at
HLA-DQ, typing was available for 90% of donor–
recipient pairs (N 5 641), and most pairs (N 5 577;
90%) were matched at this locus. Death from infection,
interstitial pneumonitis, and organ failure were more
likely after 1- and 2-loci mismatched transplantations
compared with matched transplantations. Disease
status at transplantation is a predictor of mortality
and a modifiable factor for many patients through
early referral for HSCT. Mortality rates were higher
when patients were not in remission at transplantation
(RR5 1.42, 95% CI: 1.16-1.74, P\ .001). This effect
is independent of donor–recipient HLAmismatch. Pa-
tients .60 years old (RR 5 1.41, 95% CI: 1.13-1.76,
P 5 .002) and those with a performance score \90
at transplantation (RR 5 1.39, 95% CI: 1.12-1.71,
P 5 .003) experienced higher mortality.
We specifically explored for an effect of donor age,
donor–recipient sex match, cytomegalovirus (CMV)
Table 2. Results of Multivariate Analysis
Outcome Hazard Ratio (95% Confidence Interval) P Value
Grade 2-4 acute GVHD
Donor-recipient HLA match
Matched at HLA-A, -B, -C, -DRB1 1.00
Mismatched at 1 or 2 HLA-loci 1.32 (1.05-1.65) .015
In vivo T cell depletion
Non-TBI regimens with in vivo T cell depletion 1.00
TBI regimens without in vivo T cell depletion 1.64 (1.23-2.18) .0007
Non-TBI regimens without in vivo T cell depletion 1.73 (1.34-2.24) <.0001
TBI regimens with in vivo T cell depletion 1.03 (0.59-1.80) .92
Grade 3-4 acute GVHD
Donor-recipient HLA match
Matched at HLA-A, -B, -C, -DRB1 1.00
Mismatched at 1 or 2 HLA-loci 1.87 (1.34-2.60) .0002
In vivo T cell depletion
Non-TBI regimens with in vivo T cell depletion 1.00
TBI regimens without in vivo T cell depletion 1.23 (0.76-2.00) .39
Non-TBI regimens without in vivo T cell depletion 1.75 (1.17-2.61) .006
TBI regimens with in vivo T cell depletion 1.01 (0.42-2.39) .99
GVHD prophylaxis
Cyclosporine-containing regimens 1.00
Tacrolimus-containing regimens 0.65 (0.46-0.92) .014
Chronic GVHD
In vivo T cell depletion
Non-TBI regimens with in vivo T cell depletion 1.00
TBI regimens without in vivo T cell depletion 2.35 (1.76-3.14) <.0001
Non-TBI regimens without in vivo T cell depletion 2.18 (1.67-2.84) <.0001
TBI regimens with in vivo T cell depletion 1.48 (0.81-2.70) .20
Overall mortality
Donor-recipient HLA match
Matched at HLA-A, -B, -C, -DRB1 1.00
Mismatched at 1 HLA-locus 1.18 (0.94-1.48) .15
Mismatched at 2 HLA-loci 2.34 (1.62-3.37) <.0001
Recipient age
18-50 years 1.00
>50 years 1.31 (0.105-1.65) .018
Recipient performance score
90-100 1.00
#80 1.39 (1.12-1.72) .003
Disease status at transplantation
Remission 1.00
Relapse or primary induction failure 1.51 (1.23-1.85) <.0001
TBI indicates total body irradiation; GVHD, graft-versus-host disease.
1872 Biol Blood Marrow Transplant 17:1855-1877, 2011J. R. Passweg et al.serostatus, and ABO compatibility and did not find an
association among these characteristics and graft fail-
ure, GVHD, or survival. Our findings are consistentFigure 1. Probabilities of OS after HLA-matched (A), 1-locus
mismatched (B), and 2-loci mismatched (C) unrelated donor trans-
plantation adjusted for patient age, performance score, and disease sta-
tus at transplantation. The 5-year probabilities are 37% (95% CI: 32-42),
30% (95% CI: 22-38), and 16% (95% CI: 6-31) after HLA-matched,
1-locus mismatched, and 2-loci mismatched unrelated donor trans-
plants, respectively.with a recent report that considered donor–recipient
matching at the allele-level for HLA-A, -B, -C, and
-DRB1 after URD HSCT with myeloablative condi-
tioning for hematologic malignancies [5]. A likely
explanation for our inability to detect differences in
HSCT outcomes by donor age could be because of
the fact that only 5% of donors were older than 50. Al-
though the National Donor Marrow Program guide-
line limit for donor age is 18 to 60 years, the current
study population suggests that approximately 70% of
adult donors called to donate are 18 to 40 years old.
The selection of younger donors by transplant physi-
cians effectively prevents us from further exploring
the effect of donor age on transplantation outcomes.
Others have shown that GVHD and mortality risks
are higher in male recipients of female donors when
the donor is a matched sibling [14], and, more recently,
these findings were confirmed in another report [15].
In that report [15], 75% of transplantations used
were matched sibling donors, most received myeloa-
blative conditioning regimens, and the observed effect
Biol Blood Marrow Transplant 17:1855-1877, 2011 1873Donor Characteristics and RIC Transplantsof donor–recipient sex match was most pronounced
for chronic myeloid leukemia (CML) and myeloma.
Our inability to observe an effect of donor–recipient
sex match on HSCT outcomes may be explained by
differences in the study population. Our report is lim-
ited to recipients of URD HSCT with RIC regimens,
donor–recipient matching considered allele-level
HLA typing at HLA-A, -B, -C, and -DRB1, only
10% of patients in the current analysis had CML and
there were no patients with myeloma. Patients with
myeloma were excluded, because URD HSCT is not
considered first-line treatment. Importantly, our ob-
servations are consistent with a large series on URD
HSCT with myeloablative conditioning regimens [5].
Our findings have important implications for se-
lecting adult unrelated donors when considering RIC
regimens for patients with hematologic malignancies.
Survival rates are highest with donor–recipient pairs
matched at HLA-A, -B, -C, and -DRB1. Avoiding
transplantation of bonemarrow grafts and transplanta-
tion of PBPCs will lower graft failure rates.ACKNOWLEDGMENTS
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